Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 254 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Maximum Tolerated Dose Clear all

Conditions: Oral Mucositis, Hematopoietic Stem Cell Transplantation
Interventions: Palifermin; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 18 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Schizophrenia
Interventions: DSP-1349M, placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Superficial Basal Cell Carcinoma
Interventions: PEP005; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 9
States / cities: Mesa, Arizona • Oceanside, California • San Diego, California + 6 more

Conditions: Cancers
Interventions: NM6603; Drug
Lead sponsor: NucMito Pharmaceuticals Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Detroit, Michigan • Cleveland, Ohio • Nashville, Tennessee + 1 more

Conditions: Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Pelham, Alabama • Los Angeles, California • Santa Ana, California + 17 more

Conditions: Colorectal Cancer
Interventions: SC-006, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Ann Arbor, Michigan + 6 more

Conditions: Inoperable Solid Tumors or Lymphomas
Interventions: AvidinOX, 177Lu-ST2210; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: MLN9708; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more

Conditions: Advanced Solid Tumors
Interventions: BAY2416964, Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Altamonte Springs, Florida • Sarasota, Florida • Detroit, Michigan + 3 more

Conditions: Metastatic Colorectal Cancer
Interventions: TF2/IMP288; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions: ABT-199, Rituximab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Chicago, Illinois • New Hyde Park, New York + 1 more

Conditions: Advanced Cancer, Refractory Cancer
Interventions: AV-412; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Kansas City, Kansas • Boston, Massachusetts + 1 more

Conditions: Leukemia, Myeloid, Acute
Interventions: decitabine iv, volasertib iv infusion; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 65 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Houston, Texas

Conditions: Medical Oncology
Interventions: BAY1187982; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: San Francisco, California • Santa Monica, California • New Haven, Connecticut + 7 more

Conditions: Osteosarcoma, Bone Metastases
Interventions: 153Sm-DOTMP, External beam radiotherapy., Calcium Carbonate, Mozobil, Neupogen Injectable Product; Drug · Radiation
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 15 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma, Wilm's Tumor
Interventions: RO4929097, Dexamethasone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Bethesda, Maryland • Memphis, Tennessee

Conditions: Ovarian Cancer
Interventions: CC-5013, liposomal doxorubicin; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: San Francisco, California • Orlando, Florida • New York, New York + 2 more

Conditions: T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
Interventions: Rituximab, Etoposide, Siplizumab, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma
Interventions: BI 2536; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Omaha, Nebraska • Rochester, New York + 1 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Dose escalation followed by treatment with MTD; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado • Boston, Massachusetts

Conditions: Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Promyelocytic, Acute, Sarcoma
Interventions: TURALIO(R); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 35 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
Interventions: NDI-101150, Pembrolizumab; Drug
Lead sponsor: Nimbus Saturn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more

Conditions: Pheochromocytoma, Paraganglioma
Interventions: Ultratrace Iobenguane (MIBG) I 131; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Providence, Rhode Island

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: CC-4047; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Cleveland, Ohio

Search by objective public record fields.

Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

A Phase 1 Study of NM6603 in Advanced Solid Tumors

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

A Study of NDI 1150-101 in Patients With Solid Tumors

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment